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median Karnofsky (KPS) score prior to transplant was 90
(range: 70-100); those who received plerixafor (n¼88) ten-
ded to have lower KPS vs. G-CSF alone (n¼41; p¼.07). Median
age of the cohort was 54 years (range: 19-76), with HL pts
younger than NHL pts (median: 37 vs. 60 years). Ability to
collect >2x106 /kg CD34+ cells on day 1 was highly associ-
ated with achieving a total yield of >5x106 /kg CD34+ cells
(OR¼41.6; p<.001). Both collection goals were signiﬁcantly
associated with earlier time to ANC engraftment (p<.001). In
the 88 pts who received plerixafor (75 NHL pts), the median
number of doses was 2 (range: 1-3); 76% received their ﬁrst
dose on day 4 (range: 4-7). Patients who received day 4
plerixafor had signiﬁcantly lower CD34 counts on day 4 than
those that received G-CSF alone (p<.001). Plerixafor use was
highly associated with>2x106 /kg on ﬁrst collection (p¼.03),
but not with the total number of collections or the ability to
achieve a total yield of >5x106 /kg CD34+ cells. However,
whether or not pts got plerixafor on day 4 vs. later was
signiﬁcantly associated with sufﬁcient total CD34+ cell yield
(37% vs. 10%; p¼.016).
Conclusions: Pts who received planned plerixafor on day 4
were more likely to achieve the target yield despite having
risk factors for mobilization failure. Routine use of plerixafor
in lymphoma pts who are less likely to be poor mobilizers
may lead to fewer apheresis procedures, faster engraftment,
and shorter hospital stays. The potential economic beneﬁts of
this strategy warrant further investigation.Table 1
Data Summary
Variables Group A, N¼16 Group B, N¼16
Age* (yrs) 58 (39-72) 58 (49-68)
KPS* (%) 70 (60-80) 70 (60-80)
Creatinine Clearance
pre 2nd ASCT* (ml/min)
76 (42-129) 108 (44-218)
CR pre- 2nd ASCT [n (%)] 2 (12) 3 (14)
CD34+ cells infused for 2nd
ASCT* (x 106 cells/kg)
3.35 (2.2-10.7) 3.12 (2.79-12.04)
Febrile Neutropenia [n (%)] 10 (63) 16 (100)
In-patient stay for
2nd ASCT* (days)
15 (12-24) 23 (19-51)
CR at Day +100 post
2nd ASCT [n (%)]
2{ (14) 7x (47)
KPS- Karnofsky’s Performance score
CR- Complete response
ASCT- Autologous Stem cell transplant
* Values are median with range in parenthesis
{Day +100 response data not available for 2 patients in Group A
x Day +100 response data not available for 1 patient in Group B141
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Objetives: G-CSF has shown to shorten time to neutrophil
engraftment in autologous peripheral blood hematopoietic
stem cell transplantation (Auto-HSCT). Two ﬁlgrastim phar-
macological presentations exist for clinical use, non-pegy-
lated and pegylated. Our aim was to compare clinical
outcomes in using as support Peg-Filgrastim (PEG-F)or Fil-
grastim (F) in a group of adults undergoing autologous HSCT.
Methods: From 2010 to 2012, 69 adult patients underwent
Auto-HSTC in our BMT unit. Attending physician decided
the allocation to PEG-F or F. Other support measures
were standardized in all patients. An independent reviewer
collected data from medical records. Descriptive analyses
were carried-out as well as Kaplan-Meier survival estimates.
Results: From69 included subjects, 50 received PEG-F and 19
F. Median age was 46 vs 54 for PEG-F vs. F (P¼.05). There was
no difference by gender, body weight, diagnoses, condi-
tioning regimen, or CD34+ cells infused. Most common
diagnoses were Multiple Myeloma (48%) and Hodgkin lym-
phoma (28%). In concordance with diagnoses, Melphalan
(52%) and BEAM (46%) were the conditioning regimens most
commonly used. Median CD34+ (x106)/Kg preserved were
4.3 for PEG-F vs. 3.9 for F, (P¼.61). Median initiation of PEG-F
was 7 days after cell infusion compared to 3 days for F; P<.01.
We did not have transplant mortality death. Neutropenicfever was equal among groups (58% vs 47%). Median
number of days to achieve 500 neutrophils was 12 vs 11
(PEG-F vs F); P<.01. All patients showed neutrophil and
platelet engraftment.
Conclusions: We did not ﬁnd clinically relevant differences
among the effects of the two pharmacological ﬁlgrastim
presentations. We also found that 4 day difference in starting
the drug only represented 1 day of delay in neutrophil
engraftment without clinical repercussions. Now, we
considered changing our clinical practice by introducing
PEG-F for all patients, taking into consideration ease of
application and economical consideration.142
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Background: Salvage ASCT is increasingly utilized for
eligible MM patients (pts). High dose melphalan (HDM) is
the standard conditioning used for 1st ASCT. Despite con-
cerns for resistance, HDM is predominantly used as condi-
tioning regimen for 2nd / or salvage ASCT. BEAM (Carmustine,
etoposide, Ara-C and Melphalan) has shown superior PFS
and OS compared to HDM during 1st ASCT for MM pts. We
conducted a single institution retrospective analysis to
evaluate response and toxicity with BEAM conditioning in
2ndASCT.
Methods: Thirty two pts who received 2nd ASCT for MM
(2007-2013) were identiﬁed. Sixteen pts received HDM (140-
200mg/m2; Group A) and an equal number received BEAM
(carmustine 300 mg/m2, etoposide 100 mg/m2, cytarabine
100 mg/m2, and melphalan 140 mg/m2; Group B). Patient
characteristics, toxicity and response at day 100 were
collected and compared between the 2 groups. Fischer’s
